A researcher looking into a microscope (left); A researcher holding a tool

Respiratory Researchers Share Findings at International Thoracic Conference

June 27, 2025 – Researchers from Seattle Children’s Research Institute shared findings to more efficiently treat, cure and diagnose asthma, cystic fibrosis, bronchopulmonary dysplasia and more at the annual American Thoracic Society (ATS) International Conference, held May 18 to May 21 in San Francisco.

Thirty-three oral and poster abstracts were presented by 24 researchers from the Center for Respiratory Biology and Therapeutics (CRBT), alongside additional Children’s researchers. Each year, nearly 14,000 researchers from around the world attend the conference to learn about the latest advances in respiratory research, interact with international colleagues and kindle new collaborations. Seattle Children’s stood out as a leader in the field, highlighting the depth, innovation and impact of its respiratory research program on a global stage.

“The ATS conference is the biggest and one of the most important meetings where researchers and clinicians across pulmonary, critical care and sleep medicine present their work on a global stage,” said CRBT Director Jason Debley, MD, MPH. “It serves as the premier platform for unveiling cutting-edge respiratory research from basic through translational, clinical, epidemiologic, community and global health and brings together physicians, basic researchers, nurses, respiratory therapists and industry leaders, fostering cross-disciplinary dialogue and partnerships.”

Seattle Children’s, and the Center for Respiratory Biology and Therapeutics in particular, has a large presence at ATS annually, with many CRBT faculty across several Seattle Children’s clinical divisions selected each year to present their work in prestigious scientific ATS symposia.

— Jason Debley, MD, MPH, Director, Center for Respiratory Biology and Therapeutics

The Debley Lab researches the role airway epithelial cells (cells lining the airway) play in asthma, health and lung development. Dr. Debley, his lab team and faculty mentees presented at this year’s ATS.

Two researchers discuss a report on a computer screen

One of Dr. Debley’s symposium talks, sponsored by NIH, shared results from a study that explored why children with exacerbation-prone asthma are more vulnerable to infection with rhinovirus, the virus responsible for the common cold. The study found that airway epithelial cells from these children permit excessive replication of the virus due to weaker baseline immune activity which then leads to excessive airway inflammation following infection.

In this work, the Debley lab observed that treating airway cells from exacerbation-prone children with a specific immune-boosting protein (Interferon-β) markedly reduced replication of rhinovirus and calmed secondary exaggerated immune and inflammatory responses, suggesting a possible way to prevent asthma attacks triggered by rhinovirus infections.  This work not only sets the stage for future trials to prevent exacerbations and improve baseline lung function in exacerbation-prone children, but also identifies novel therapeutic targets.

“I believe that by learning from patients and applying cutting-edge research tools and techniques to human cell and tissue model systems from children with and without asthma, we can greatly advance our understanding of how airway epithelial cells respond to viral infections and environmental factors (e.g. smoke, pollens, etc.), leading to airway inflammation and injury,” Dr. Debley said. “By understanding these mechanisms, we can develop better treatments and hopefully, a cure for asthma someday.”

Oral abstracts presented by CRBT researchers also include:

From Cradle to Chronic Disease: Diagnosis and Timely Treatment

“Premature birth accounts for 10% of live births and disrupts normal airway development. Adult survivors of premature birth develop lifelong airway disease and early-onset chronic obstructive pulmonary disease. Yet, we lack targeted therapies to achieve and sustain normal lung function. Our research has identified that cells that line the airways of premature infants make more of a protein called vimentin; this protein may change the structure of the airway and cause airway obstruction. We hope this discovery will enable earlier identification of airway disease in premature infants and guide future development of targeted therapies.”

Laurie Eldredge, MD, PhD, principal investigator, and Yan Han, research scientist, Eldredge Lab

Safer, Non-Surgical Ways to Improve Lung Function Over Time

“My research crosses the fields of early onset scoliosis in young children and quantitative respiratory assessments in pediatrics. I work with spine surgeons internationally to develop new surgical and non-surgical ways to maximize lung function over time. This includes measuring functional outcomes as spine deformities progress and as they are treated.”

Greg Redding, MD, principal investigator, Pulmonary and Sleep Medicine

Exploring Asthma at the Cellular Level

“DNA methylation is one of the ways that our cells integrate signals from the environment and experiences to change how they function and turn genes on and off. We looked at how DNA methylation changes in airway cells after infection with rhinovirus or exposure to the cytokine IL-13 (which is increased with allergic inflammation) and found that both lead to changes at multiple sites in the genome and change gene expression. Future work is planned to look at how these changes in cells explain why children are more prone to asthma and to asthma exacerbations triggered by viral infections.”

Weston Powell, MD, PhD, principal investigator, Powell Lab / Debley Lab

Wider and Better Outcomes for Cystic Fibrosis

“I had a young girl with cystic fibrosis who had such severe lung disease that she couldn’t attend school and couldn’t sleep at night due to her cough. She inspired me to research what is causing some patients to have very severe lung disease despite getting lots of medications and therapies. Our current research has found that Latino children with cystic fibrosis and CFTR-related metabolic syndrome (CRMS) had less healthy bacteria, more pathogenic bacteria, and increased inflammation in their airways compared to non-Latino children.”

Meghan McGarry, MD, MAS, principal investigator, McGarry Lab

Empowering the Next Generation of Research Leaders

 Terri Laguna, MD, MSc, division head of pulmonary and sleep medicine at Seattle Children’s and cystic fibrosis researcher at the Laguna Lab presented research and was the featured speaker at one of the conference’s forums, encouraging authentic and representative scientific leaders in research.

Seattle Children’s Researchers Present Posters and Talks at ATS Conference

Several other scientists and physician-researchers from Seattle Children’s contributed the following posters and presentations at ATS:

Jason Debley, MD, MPH

Jessica Clarion, MD, pediatric pulmonary fellow

Mary Crocker, MD, MPH, principal investigator, Crocker Research Program

Sydney Clark, research scientist, Reeves Lab

Camille Gates, research technician, Debley Lab

Gail Deutsch, MD, associate CRBT center director, pathologist

Matt Fought, research scientist, Laguna Lab

Courtney Gallagher, MD, physician

Blair Mockler, MD, pediatric pulmonary fellow

Laura Ellington, MD, MS, principal investigator, Ellington Lab

Weston Powell, MD, PhD, Powell Lab

Rebecca Spurr, MD, pediatric pulmonary fellow

MacKenzie Wyatt, MD, pediatric pulmonary fellow

Ben Wilfond, MD, principal investigator, Wilfond Lab

  • The Ethical Importance of Community Partnerships: Challenges and Opportunities

Elizabeth Vanderwall, research scientist, Debley Lab

— Empress Rivera-Ruiz

Further Reading

About the Center for Respiratory Biology and Therapeutics

Unifying basic, translational, clinical, epidemiologic and global health research, the physician-scientists at Seattle Children’s Center for Respiratory Biology and Therapeutics are leading transformative “bench to bedside and back” efforts to drive the next phase of discoveries and novel therapeutics for pediatric respiratory diseases.